Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...

Trying to figure out what to do with Intellia Therapeutics stock? You’re definitely not alone. After all, this is a company that’s been on quite the rollercoaster lately. Over just the past week, ...

As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in coming days, analysts and especially investors will keep their eyes on whether the ...

As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...

Attempting to cash in on what's likely to be a relatively short-lived mania isn't a good idea for most investors most of the ...

CRISPR Therapeutics’ stock is surging as in-vivo therapies show promise. Learn about CRSP stock's risks, long-term upside, ...

Biotech company Metagenomi (NASDAQ:MGX) is utilizing artificial intelligence chips from Amazon Web Services (AMZN) to enhance ...

Ark Invest bought shares of Alibaba, Intellia Therapeutics, and Baidu on Monday. Alibaba and Baidu are surging Chinese e-commerce stocks that have emerged as AI plays. Intellia shares have almost ...

As a cornerstone of Indian agriculture and a critical contributor to the national economy and food security across Asia, rice presents both enormous opportunities and pressing challenges. Modern gene ...